Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc Com V.ICO


Primary Symbol: ICOTF

iCo Therapeutics Inc is a Canada based biotechnology company. It is involved in the Research and development of ophthalmic indications. The company identifies, develops, and commercialize drug candidates with clinical history, and re-doses, reformulates and develops these drug candidates to treat sight and life-threatening diseases. Its in-licensed assets are iCo-008 and the Oral AmpB Delivery System. iCo-008 is a human monoclonal antibody targeting eotaxin-1 that acts as a messenger between...


GREY:ICOTF - Post by User

Comment by YanTheDonon Jun 20, 2018 12:34pm
55 Views
Post# 28199504

RE:FredZarfloon your are are brown

RE:FredZarfloon your are are brown
Rocketred2015 wrote:
your so full of chit it stinks in the room


what did he say that was wrong....the link he posted was from february, but as of last week, check the article below. Either way this doesnt look good. You have to be wary in all situations.



9:08AM ET on Friday Jun 08, 2018 by MT Newswires
 

09:08 AM EDT, 06/08/2018 (MT Newswires) -- Immune Pharmaceuticals (IMNP), a biopharmaceutical company, said pre-market Friday that it has received a letter from the listing qualifications department of the Nasdaq Stock Market.

The letter indicates that Immune's failure to regain compliance with the minimum $1.00 bid price requirement by May 30 could serve as a basis for the delisting of the company's shares from the Nasdaq Capital Market unless the company makes a timely request for a hearing before the Nasdaq hearings panel.

The company said it plans to request a hearing before the panel, when it said it will will present its plan to show compliance with the bid price requirement and request an extension of time within which to do so.

Immune said it continues to execute its strategic plan for the development of its core assets, and it continues to actively explore strategic options with respect to its oncology and other non-core assets.

Shares closed at $0.2349 on Thursday, up 0.4% on the day.

Price: 0.2349, Change: +0.0009, Percent Change: +0.38

<< Previous
Bullboard Posts
Next >>